Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
Identifieur interne : 000265 ( Main/Exploration ); précédent : 000264; suivant : 000266Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
Auteurs : Gayathri Baburaj [Inde] ; Levin Thomas [Inde] ; Mahadev Rao [Inde]Source :
- Archives of medical research [ 1873-5487 ] ; 2021.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Antinéoplasiques, Antiviraux.
- traitement médicamenteux : Tumeurs du poumon.
- Humains, Interactions médicamenteuses, Pandémies, Repositionnement des médicaments.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Antineoplastic Agents, Antiviral Agents.
- drug therapy : COVID-19, Lung Neoplasms.
- epidemiology : COVID-19.
- pathogenicity : SARS-CoV-2.
- Drug Interactions, Drug Repositioning, Humans, Pandemics.
Abstract
Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition.
DOI: 10.1016/j.arcmed.2020.11.006
PubMed: 33257051
PubMed Central: PMC7670900
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.</title><author><name sortKey="Baburaj, Gayathri" sort="Baburaj, Gayathri" uniqKey="Baburaj G" first="Gayathri" last="Baburaj">Gayathri Baburaj</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Levin" sort="Thomas, Levin" uniqKey="Thomas L" first="Levin" last="Thomas">Levin Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author><author><name sortKey="Rao, Mahadev" sort="Rao, Mahadev" uniqKey="Rao M" first="Mahadev" last="Rao">Mahadev Rao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Electronic address: mahadev.rao@manipal.edu.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33257051</idno><idno type="pmid">33257051</idno><idno type="doi">10.1016/j.arcmed.2020.11.006</idno><idno type="pmc">PMC7670900</idno><idno type="wicri:Area/Main/Corpus">000745</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000745</idno><idno type="wicri:Area/Main/Curation">000745</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000745</idno><idno type="wicri:Area/Main/Exploration">000745</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.</title><author><name sortKey="Baburaj, Gayathri" sort="Baburaj, Gayathri" uniqKey="Baburaj G" first="Gayathri" last="Baburaj">Gayathri Baburaj</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author><author><name sortKey="Thomas, Levin" sort="Thomas, Levin" uniqKey="Thomas L" first="Levin" last="Thomas">Levin Thomas</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author><author><name sortKey="Rao, Mahadev" sort="Rao, Mahadev" uniqKey="Rao M" first="Mahadev" last="Rao">Mahadev Rao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Electronic address: mahadev.rao@manipal.edu.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka</wicri:regionArea><wicri:noRegion>Karnataka</wicri:noRegion></affiliation></author></analytic><series><title level="j">Archives of medical research</title><idno type="eISSN">1873-5487</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (pharmacology)</term><term>Antiviral Agents (pharmacology)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>Drug Interactions (MeSH)</term><term>Drug Repositioning (MeSH)</term><term>Humans (MeSH)</term><term>Lung Neoplasms (drug therapy)</term><term>Pandemics (MeSH)</term><term>SARS-CoV-2 (pathogenicity)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antinéoplasiques (pharmacologie)</term><term>Antiviraux (pharmacologie)</term><term>Humains (MeSH)</term><term>Interactions médicamenteuses (MeSH)</term><term>Pandémies (MeSH)</term><term>Repositionnement des médicaments (MeSH)</term><term>Tumeurs du poumon (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antineoplastic Agents</term><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term><term>Lung Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antinéoplasiques</term><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du poumon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Interactions</term><term>Drug Repositioning</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Interactions médicamenteuses</term><term>Pandémies</term><term>Repositionnement des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33257051</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-5487</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>04</Month></PubDate></JournalIssue><Title>Archives of medical research</Title><ISOAbbreviation>Arch Med Res</ISOAbbreviation></Journal><ArticleTitle>Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.</ArticleTitle><Pagination><MedlinePgn>261-269</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0188-4409(20)31189-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.arcmed.2020.11.006</ELocationID><Abstract><AbstractText>Lung cancer patients are at heightened risk for developing COVID-19 infection as well as complications due to multiple risk factors such as underlying malignancy, anti-cancer treatment induced immunosuppression, additional comorbidities and history of smoking. Recent literatures have reported a significant proportion of lung cancer patients coinfected with COVID-19. Chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, oseltamivir, remdesivir, favipiravir, and umifenovir represent the major repurposed drugs used as potential experimental agents for COVID-19 whereas azithromycin, dexamethasone, tocilizumab, sarilumab, famotidine and ceftriaxone are some of the supporting agents that are under investigation for COVID-19 management. The rationale of this review is to identify potential drug-drug interactions (DDIs) occurring in lung cancer patients receiving lung cancer medications and repurposed COVID-19 drugs using Micromedex and additional literatures. This review has identified several potential DDIs that could occur with the concomitant treatments of COVID-19 repurposed drugs and lung cancer medications. This information may be utilized by the healthcare professionals for screening and identifying potential DDIs with adverse outcomes, based on their severity and documentation levels and consequently design prophylactic and management strategies for their prevention. Identification, reporting and management of DDIs and dissemination of related information should be a major consideration in the delivery of lung cancer care during this ongoing COVID-19 pandemic for better patient outcomes and updating guidelines for safer prescribing practices in this coinfected condition.</AbstractText><CopyrightInformation>Copyright © 2020 IMSS. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baburaj</LastName><ForeName>Gayathri</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Levin</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Mahadev</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India. Electronic address: mahadev.rao@manipal.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Med Res</MedlineTA><NlmUniqueID>9312706</NlmUniqueID><ISSNLinking>0188-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">Chemotherapy</Keyword><Keyword MajorTopicYN="Y">Drug-drug interactions</Keyword><Keyword MajorTopicYN="Y">Lung cancer</Keyword><Keyword MajorTopicYN="Y">QT prolongation</Keyword><Keyword MajorTopicYN="Y">Tyrosine kinase inhibitors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33257051</ArticleId><ArticleId IdType="pii">S0188-4409(20)31189-9</ArticleId><ArticleId IdType="doi">10.1016/j.arcmed.2020.11.006</ArticleId><ArticleId IdType="pmc">PMC7670900</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li></country></list><tree><country name="Inde"><noRegion><name sortKey="Baburaj, Gayathri" sort="Baburaj, Gayathri" uniqKey="Baburaj G" first="Gayathri" last="Baburaj">Gayathri Baburaj</name></noRegion><name sortKey="Rao, Mahadev" sort="Rao, Mahadev" uniqKey="Rao M" first="Mahadev" last="Rao">Mahadev Rao</name><name sortKey="Thomas, Levin" sort="Thomas, Levin" uniqKey="Thomas L" first="Levin" last="Thomas">Levin Thomas</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000265 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000265 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33257051
|texte= Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33257051" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |